150806-61-4

Upstream product

• 909114-65-4 tert-butyl 4,6-dimethoxy-1,3,5-triazinyl carbonate 
• 103-01-5 N-Phenylglycine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 169268-95-5 tert-butyl allyl(phenyl)carbamate 
• 2835-06-5 phenylglycin 

Downstream Products

• 185525-77-3 [1(R)-[(2,3-dihydrospiro[1H-indene-1,4'-piperidin]-1'-yl)carbonyl]-1-phenylmethyl]carbamic acid 1,1-dimethylethyl ester 
• 166739-13-5 N-(tert-butoxycarbonyl)-D-cyclohexylglycine 
• 179173-77-4 1-[[1-(N-Phenylamino)acetyl-4-piperidyl]methyl]-1H-2-methylimidazo[4,5-c]pyridine 
• 1056652-18-6 C₂₀H₂₅N₃O₅S 
• 1224936-23-5 C₁₆H₁₉N₃O₃ 

Relevant academic research and scientific papers

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Fused imidazole compounds with indoleamine 2,3-dioxygenase inhibition activity

The invention relates to fused imidazole compounds, and a preparation method and application thereof. The structure of the compounds is shown in a general formula I, wherein the definitions of each group are as described in the specification. The compounds are capable of selectively inhibiting indoleamine 2,3-dioxygenase (IDO). The compounds provided by the invention can be used as IDO inhibitorsfor the treatment and/or prevention of diseases with the pathological characteristics of IDO mediated tryptophan metabolism pathways, such as cancer, eye diseases, autoimmune diseases, psychological disorders, depression, anxiety and other diseases.

1,2-NAPHTHOQUINONE DERIVATIVE AND METHOD FOR PREPARING SAME

Disclosed are a compound represented by Formula (1), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, tautomer, enantiomer, or pharmaceutically acceptable diastereomer thereof, a method of preparing the same, and a pharmaceutical composition, which have effects for treatment or prevention of metabolic syndromes, comprising the same: wherein R1to R6, X1 to X4, and n are the same as defined in Claim 1.

Use of the composite material RuO2/BaTi4O9 as an environmentally benign solid catalyst for the oxidative cleavage of olefins

Catalytic use of a composite material, RuO2/BaTi 4O9, in combination with NaIO4 in EtOAc-H 2O has been shown to efficiently cleave alkenes, affording ketones, aldehydes and/or carboxylic acids in high yields. Georg Thieme Verlag Stuttgart.

NOVEL COMPOUNDS

This invention relates to novel amide derivatives and salts thereof. More particularly, it relates to novel amide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease.

Useful reagents for introduction of Boc and Fmoc protective groups to amines: Boc-DMT and Fmoc-DMT

New amino-protecting reagents, Boc-DMT and Fmoc-DMT, were prepared, and found to be useful for the introduction of Boc and Fmoc groups into amines. Both the reagents can protect various amines including amino acids in good yield in aqueous media. Since the reagents are neither unstable nor irritating, they are practically useful. Georg Thieme Verlag Stuttgart.

PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS

Compounds are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis.

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists having the structure, for example, of STR1 for example STR2

Proline derivatives possessing prolyl endopeptidase-inhibitory activity

Novel proline derivatives of the following formula (I) STR1 wherein each symbol is as defined in the specification, which specifically inhibit prolyl endopeptidase activity and can be used for the prevention and/or treatment of dementia and amnesia as agents which act directly on the central symptoms of dementia.